Fannie Mae, Freddie Mac shares tumble after conservatorship comments
BeyondSpring Inc . (NASDAQ:BYSI), a biotechnology company with a market capitalization of $92.32 million and current share price of $2.23, announced Thursday that it has scheduled its 2025 annual meeting of shareholders for September 15, 2025. The meeting comes just days after the company’s scheduled September 5 earnings release. The company set the record date for the meeting as the close of business on July 25, 2025.
Shareholder proposals intended for inclusion in the proxy statement under Rule 14a-8 of the Securities Exchange Act must be received at BeyondSpring’s principal executive offices in Florham Park, New Jersey, by the close of business on July 14, 2025. Proposals must also comply with all other requirements of Rule 14a-8 to be considered for inclusion.
Further details regarding the exact time and location of the 2025 annual meeting will be provided in the company’s proxy statement, which will be filed with the Securities and Exchange Commission ahead of the meeting.
The information in this article is based on a press release statement contained in a filing with the SEC.
In other recent news, BeyondSpring Inc. has shared interim phase 2 data from a study involving patients with metastatic non-small cell lung cancer (NSCLC) who had previously progressed on PD-1/L1 inhibitors. The data, presented at the American Society of Clinical Oncology Annual Meeting, highlighted positive results for the combination therapy of Plinabulin with pembrolizumab and docetaxel. The study, which included 47 patients, showed a median progression-free survival of 6.8 months, nearly doubling the 3.7 months observed with the current standard of care, docetaxel. Additionally, the disease control rate was reported at 77.3%, indicating that a majority of the patients experienced clinical benefits. The 15-month overall survival rate stood at 78%, with the median overall survival not yet reached. The objective response rate was 18.2%, surpassing the 12.8% seen with docetaxel alone, and the median duration of response was 7.2 months. Treatment was generally well tolerated, with no treatment-related deaths reported, although 51.1% of patients experienced grade 3 or higher adverse effects. Dr. Lan Huang, CEO of BeyondSpring, noted the potential of Plinabulin to address resistance to checkpoint inhibitors, a significant challenge in oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.